| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
1 Department of Medical Microbiology and Immunology, Southern Illinois University School of Medicine, Springfield, Illinois; 2 Akita Red Cross Hospital, Akita city, Japan; 3 Universite Montepillar II, Montepillar, France; and 4 Department of Physiology, Southern Illinois University School of Medicine, Carbondale, Illinois
PTEN (phosphatase and tensin homologue deleted on chromosome 10) has been shown to be inactivated in a wide variety of cancers, and the role of this gene as a tumor suppressor has been well established. On the other hand, results of recent animal studies as well as clinical evidence indicate that PTEN is also involved in tumor metastasis suppression. Although PTEN is known to play a key role in controlling cell growth and apoptosis, how PTEN exerts the metastasis suppressor function remains largely unknown. Recently, a microarray analysis identified the Drg-1 gene (differentiation related gene 1) as one of the potential targets of PTEN. The Drg-1 gene has been shown to suppress tumor metastasis in animal models of prostate and colon cancer, and the expression of this gene is significantly reduced with advancement of prostate and breast cancers in clinical setting. In this study, we explored the possibility that PTEN controls tumor metastasis by regulating the expression of the Drg-1 gene. Our results indicate that overexpression of PTEN significantly augments the endogenous expression of Drg-1 protein, whereas inhibition of PTEN by small interfering RNA decreases Drg-1 in a dose- and time-dependent manner. We also found that the control of the Drg-1 gene by PTEN seems to be at the transcriptional level, and that a phospho-Akt inhibitor restores the Drg-1 expression, indicating that PTEN controls Drg-1 by an Akt-dependent pathway. Consistent with these results, our immunohistochemical analysis revealed that PTEN expression correlates significantly with Drg-1 in both prostate and breast cancer cases. Furthermore, combination of the two markers, PTEN and Drg-1, emerged as a significantly better predictor of prostate and breast cancer patient survival than either marker alone.
This article has been cited by other articles:
|
|
 |
|
  T. P. Ellen, Q. Ke, P. Zhang, and M. Costa NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states Carcinogenesis, January 1, 2008; 29(1): 2 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-H. Zhang, J. N. Rao, T. Zou, L. Liu, B. S. Marasa, L. Xiao, J. Chen, D. J. Turner, and J.-Y. Wang p53-Dependent NDRG1 expression induces inhibition of intestinal epithelial cell proliferation but not apoptosis after polyamine depletion Am J Physiol Cell Physiol, July 1, 2007; 293(1): C379 - C389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Tu, X. Yan, L. Hood, and B. Lin Proteomics Analysis of the Interactome of N-myc Downstream Regulated Gene 1 and Its Interactions with the Androgen Response Program in Prostate Cancer Cells Mol. Cell. Proteomics, April 1, 2007; 6(4): 575 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Kovacevic and D. R. Richardson The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer Carcinogenesis, December 1, 2006; 27(12): 2355 - 2366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application. Clin. Cancer Res., July 1, 2006; 12(13): 3882 - 3889. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Maruyama, M. Ono, A. Kawahara, T. Yokoyama, Y. Basaki, M. Kage, S. Aoyagi, H. Kinoshita, and M. Kuwano Tumor Growth Suppression in Pancreatic Cancer by a Putative Metastasis Suppressor Gene Cap43/NDRG1/Drg-1 through Modulation of Angiogenesis. Cancer Res., June 15, 2006; 66(12): 6233 - 6242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Li, Y. Hu, Y. Huo, M. Liu, D. Freeman, J. Gao, X. Liu, D.-C. Wu, and H. Wu PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin J. Biol. Chem., April 21, 2006; 281(16): 10663 - 10668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mimeault and S. K. Batra Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis, January 1, 2006; 27(1): 1 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gao, R. L. Wange, N. Zhang, J. J. Oppenheim, and O. M. Z. Howard Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN Blood, October 15, 2005; 106(8): 2619 - 2626. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
